Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ndovu RCT
PACTR202501689451229Phase 3Not yet recruiting
- Sponsor
- University of Nairobi
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of dolutegravir, darunavir and ritonavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University of Nairobi. Primary endpoint: Viral suppression at 6 months. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
dolutegravirdarunavirritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202501689451229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202501689451229.